摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-六氢[2,1-C][1,4]噁嗪-4(3H)-酮 | 930783-26-9

中文名称
(R)-六氢[2,1-C][1,4]噁嗪-4(3H)-酮
中文别名
——
英文名称
(R)-hexahydropyrazino[2,1-c][1,4]oxazin-4(3H)-one
英文别名
(R)-hexahydropyrazino[2,1-c][1,4]oxazin-4-one;(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-4(3H)-one;(9AR)-Hexahydropyrazino-[2,1-c][1,4]oxazin-4(3H)-one;(9aR)-1,6,7,8,9,9a-hexahydropyrazino[2,1-c][1,4]oxazin-4-one
(R)-六氢[2,1-C][1,4]噁嗪-4(3H)-酮化学式
CAS
930783-26-9
化学式
C7H12N2O2
mdl
——
分子量
156.184
InChiKey
MTCWTJKARNZOLR-ZCFIWIBFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    41.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (R)-六氢[2,1-C][1,4]噁嗪-4(3H)-酮 在 lithium aluminium tetrahydride 、 异丙醇 作用下, 以 四氢呋喃 为溶剂, 反应 2.5h, 以73%的产率得到(9aR)-八氢吡嗪并[2,1-c][1,4]恶嗪
    参考文献:
    名称:
    [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS
    [FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
    摘要:
    这项发明提供了一种化合物,其为式(Ia)或(Ib)的嘌呤类化合物:及其药学上可接受的盐,这些化合物是PI3K的抑制剂,并且对p110δ同工型具有选择性,p110δ是Ia类PI3激酶,优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱,如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
    公开号:
    WO2009053716A1
  • 作为产物:
    参考文献:
    名称:
    Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition
    摘要:
    PI3K delta is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(alpha, beta, delta) and IB (gamma), which catalyze the phosphorylation of PIP2 to PIP3. PI3K delta is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive opportunity to treat diseases where B cell activity is essential, e.g., rheumatoid arthritis. We report the discovery of novel, potent, and selective PI3K delta inhibitors and describe a structural hypothesis for isoform (alpha, beta, gamma) selectivity gained from interactions in the affinity pocket. The critical component of our initial pharmacophore for isoform selectivity was strongly associated with CYP3A4 time-dependent inhibition (TDI). We describe a variety of strategies and methods for monitoring and attenuating TDI. Ultimately, a structure-based design approach was employed to identify a suitable structural replacement for further optimization.
    DOI:
    10.1021/jm3003747
点击查看最新优质反应信息

文献信息

  • [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009053716A1
    公开(公告)日:2009-04-30
    This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    这项发明提供了一种化合物,其为式(Ia)或(Ib)的嘌呤类化合物:及其药学上可接受的盐,这些化合物是PI3K的抑制剂,并且对p110δ同工型具有选择性,p110δ是Ia类PI3激酶,优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱,如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
  • [EN] BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS<br/>[FR] PHÉNOLS À FONCTIONNALITÉ AMIDE SUBSTITUÉS PAR UN SYSTÈME CYCLIQUE BICYCLIQUE EN TANT QUE MÉDICAMENTS
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012080456A1
    公开(公告)日:2012-06-21
    This invention relates to bicyclic ring system substituted amide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    这项发明涉及通式1的双环环系统取代酰胺功能化酚,其用作CXCR2活性抑制剂,含有这些化合物的药物组合物,以及将其用作治疗和/或预防呼吸系统或消化系统疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症的药剂的方法,以及含有这些化合物的药物组合物。
  • BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS
    申请人:GIOVANNINI Riccardo
    公开号:US20120329773A1
    公开(公告)日:2012-12-27
    This invention relates to bicyclic ring system substituted amide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    这项发明涉及通式1的双环环系统取代酰胺功能化酚,其用作CXCR2活性抑制剂,含有相同化合物的药物组合物,以及将其用作治疗和/或预防呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症的药剂的方法,以及含有这些化合物的药物组合物。
  • [EN] BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS<br/>[FR] PHÉNOLS À FONCTIONNALITÉ SULFONAMIDE SUBSTITUÉE PAR UN SYSTÈME DE CYCLES BICYCLIQUE EN TANT QUE MÉDICAMENTS
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012080457A1
    公开(公告)日:2012-06-21
    This invention relates to bicyclic ring system substituted sulfonamide functionalized phenols of general formula (1), their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    这项发明涉及通式(1)的双环环系统取代磺酰胺官能化酚,其作为CXCR2活性抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防呼吸道或消化道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症的药剂的方法,以及含有这些化合物的药物组合物。
  • BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS
    申请人:GIOVANNINI Riccardo
    公开号:US20120316159A1
    公开(公告)日:2012-12-13
    This invention relates to bicyclic ring system substituted sulfonamide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    这项发明涉及一般式1的双环环系统取代磺酰胺功能化酚,其作为CXCR2活性抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防呼吸道或消化道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症的药剂的方法,以及含有这些化合物的药物组合物。
查看更多